Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries

Histopathology. 2017 Dec;71(6):1014-1017. doi: 10.1111/his.13327. Epub 2017 Sep 22.

Authors

Michael S Anglesio¹, Ciaran J O'Neill², Janine Senz³, C Blake Gilks⁴, W Glenn McCluggage⁵

Affiliations

¹ Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
² Department of Pathology, Antrim Area Hospital, Antrim, UK.
³ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
⁴ Department of Anatomic Pathology, Vancouver General Hospital, Vancouver, BC, Canada.
⁵ Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK.

PMID: 28746984
DOI: 10.1111/his.13327

No abstract available

Publication types

Letter

MeSH terms

Cystadenocarcinoma, Serous / genetics
Cystadenocarcinoma, Serous / pathology*
Fallopian Tube Neoplasms / genetics
Fallopian Tube Neoplasms / pathology*
Female
Humans
Middle Aged
Mutation
Neoplasm Recurrence, Local / genetics
Neoplasm Recurrence, Local / pathology*
Ovarian Neoplasms / genetics
Ovarian Neoplasms / pathology*
Peritoneal Neoplasms / diagnosis
Peritoneal Neoplasms / pathology
Tumor Suppressor Protein p53 / genetics*

Substances

TP53 protein, human
Tumor Suppressor Protein p53